N-5688 Niraparib, p-Toluenesulfonate Salt, >99%

Synonyms : [MK-4827]

Related Terms : [Zejula]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 42
  • 36
  • 33
  • 4,400
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 56
  • 48
  • 44
  • 5,900
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 75
  • 64
  • 59
  • 7,900
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 96
  • 82
  • 75
  • 10,100
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 143
  • 123
  • 112
  • 15,100
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 242
  • 208
  • 190
  • 25,600
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 477
  • 410
  • 375
  • 50,400
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 695
  • 598
  • 546
  • 73,400
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 1,130
  • 972
  • 889
  • 119,300
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 492.59
  • C19H20N4O•C7H8O3S
  • [1038915-73-9]

Solubility: DMSO.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Niraparib enhanced radiation-induced cytotoxicity in neuroblastoma cells.  In vivo treatment with niraparib and radiation prolonged survival of mice in a murine xenograft model of metastatic neuroblastoma when compared to single modalities.  Mueller S., et al. "Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma." Anticancer Res. 33: 755-762 (2013).
  • A phase 1 clinical trial demonstrated niraparib inhibited PARP more than 50% at doses greater than 80 mg/day and had antitumour activity at doses beyond 60 mg/day.  Antitumour activity of niraparib was reported in BRCA1 or BRCA2 mutation carriers with ovarian cancer, breast cancer, and in patients with sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer.  Sandhu S.K., et al. "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial." Lancet Oncol. 14: 882-892 (2013).
  • Related  CAS numbers: 1038915-64-8 for the hydrochloride salt; 1038915-60-4 for the free base; 1171196-88-5 for the sulfate salt.
  • Niraparib Tosylate monohydrate is the active ingredient in the drug sold under the trade name Zejula®. This drug has been approved in at least one country for use in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. NOTE: THE NIRAPARIB TOSYLATE MONOHYDRATE SOLD BY THE LC LABORATORIES IS NOT ZEJULA®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This  product is offered for R&D use in accordance with (i) 35 USC  271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in  Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in  Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977  in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law  exemptions of Canadian patent law; (vi) Section 68B of the Patents Act  of 1953 in New Zealand together with the amendment of same by the  Statutes Amendment Bill of 2002; (vii) such related legislation and/or  case law as may be or become applicable in the aforementioned countries;  and (viii) such similar laws and rules as may apply in various other  countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
1562